A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2017
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 13 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 28 Apr 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.